DrugPatentWatch Database Preview

Eribulin mesylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for eribulin mesylate and what is the scope of eribulin mesylate patent protection?

Eribulin mesylate is the generic ingredient in one branded drug marketed by Eisai Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eribulin mesylate has seventy-three patent family members in twenty-five countries.

One supplier is listed for this compound.

Summary for eribulin mesylate

International Patents:	73
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	21
Clinical Trials:	68
Patent Applications:	7
DailyMed Link:	eribulin mesylate at DailyMed

Pharmacology for eribulin mesylate

Drug Class	Microtubule Inhibitor
Physiological Effect	Microtubule Inhibition

Synonyms for eribulin mesylate

441045-17-6

AC-27728

AKOS025401973

AKOS030238218

AV9U0660CW

B-1939

C40H59NO11.CH4O3S

CHEBI:70710

CHEMBL1683544

CS-2803

D08914

E 7389

E7389

Eribulin (mesylate)

Eribulin mesilate

Eribulin mesilate (JAN)

Eribulin mesylate (USAN)

Eribulin mesylate [USAN]

Halaven

Halaven (TN)

HY-13442A

NSC-707389

QAMYWGZHLCQOOJ-WRNBYXCMSA-N

UNII-AV9U0660CW

Y1702

Z-3266

US Patents and Regulatory Information for eribulin mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010		RX	Yes	Yes			Y
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010		RX	Yes	Yes
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010		RX	Yes	Yes				Y
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010		RX	Yes	Yes
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010		RX	Yes	Yes
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010		RX	Yes	Yes

Expired US Patents for eribulin mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010

International Patents for eribulin mesylate

Country	Patent Number	Estimated Expiration
Australia	762998
China	104876896
European Patent Office	1596855
Japan	2015061845
Japan	4454151
Canada	2632433

Supplementary Protection Certificates for eribulin mesylate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1087960	1190021-4	Sweden		PRODUCT NAME: ERIBULIN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV, I SYNNERHET ERIBULINMESYLAT; REG. NO/DATE: EU/1/11/678/001-002 20110317
1087960	2011C/028	Belgium		PRODUCT NAME: ERIBULIN; AUTHORISATION NUMBER AND DATE: EU/1/11/678/001 20110317
1087960	C01087960/01	Switzerland		PRODUCT NAME: ERIBULIN; REGISTRATION NO/DATE: SWISSMEDIC 59489 20110513
1087960	25/2011	Austria		PRODUCT NAME: ERIBULIN UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/11/678/001-002 20110317
1087960	11C0038	France		PRODUCT NAME: ERIBULINE, SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER MESYLATE D'ERIBULINE; REGISTRATION NO/DATE: EU/1/11/678/001 20110317
1087960	C300493	Netherlands		PRODUCT NAME: ERIBULIN, ALSMEDE FARMACEUTISCHE ZOUTEN ERVAN, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/11/678/001-002 20110317